Up to now, the mechanisms observed widely for PI3K/AKT activation in gastric cancer include somatic activating mutations and amplifications in p110α (6–8), loss of the PTEN tumor suppressor (8), and genetic amplifications of AKT1 (9). This evidence concerns the gene AKT1 and neoplasm.